Kane Biotech Completes Final Closure of Private Share Offering
WINNIPEG, Manitoba — Kane Biotech Inc. (TSX-V: KNE, OTCQB: KNBIF), a leading player in biotechnology, has successfully completed the second and final closure of its previously announced non-brokered private placement offering. This significant step provides the company with crucial funding to propel its innovative strategies forward.
Details of the Private Placement Offering
In this closing event, Kane Biotech issued 4,235,000 common shares at a price of $0.10 per share, leading to gross proceeds of $423,500. Over the course of the entire offering, Kane has successfully issued a total of 16,985,000 shares, amounting to an aggregate consideration of $1,698,500.
Utilization of Proceeds
The net proceeds from this offering are earmarked for working capital and general corporate purposes, empowering Kane Biotech to enhance its operational capabilities.
Shareholder Arrangements
All securities related to the offering are subject to a hold period of four months and one day from their issuance date, ensuring regulatory compliance and investor protection.
Compensation for Finders
As part of this final closing, Kane Biotech has compensated eligible finders for their contributions with a cash commission of $24,510 and provided 245,100 common share broker warrants. Each warrant allows the holder to purchase one share of the company at an exercise price of $0.15 for 18 months following the offering's closure.
Strategic Vision Moving Forward
Marc Edwards, CEO of Kane Biotech, stated, "This latest financing provides Kane Biotech with the flexibility to aggressively pursue government funding opportunities and strategic investments aligning with our long-term vision. We are committed to leveraging these resources to drive growth and innovation, positioning the company for continued success in the months and years ahead." This sentiment reflects the company’s objective to not only bolster its financial standing but also to significantly impact the biotechnology sector.
About Kane Biotech
Kane Biotech Inc. is at the forefront of biotechnological advancements, focusing on the research, development, and commercialization of innovative technologies designed to prevent and eliminate microbial biofilms. The company holds an impressive portfolio of biotechnologies, possessing 65 patents and pending patents, complemented by proprietary trade secrets and trademarks.
Innovative Product Line
Among their leading products are DispersinB, coactiv+, DermaKB, and revyve, which showcase Kane's dedication to addressing biofilm-related challenges. With its robust research capabilities derived from in-house expertise and partnerships with prestigious research institutions, Kane strives to enhance its market position.
Contact Information for Further Inquiries
For more information:
Marc Edwards
Chief Executive Officer
Kane Biotech Inc
Email: medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc
Email: rdupuis@kanebiotech.com
Frequently Asked Questions
What is Kane Biotech's recent achievement?
Kane Biotech has completed the second and final closing of its non-brokered private placement offering, securing vital funding for its operations.
How much did Kane Biotech raise in the offering?
The total gross proceeds from the entire offering amounted to $1,698,500 through the issuance of 16,985,000 common shares.
What are the plans for the proceeds from the offering?
The funds raised will be utilized for working capital and general corporate purposes, enhancing the company's growth strategies.
Who can purchase shares through broker warrants?
Holders of the broker warrants can purchase shares at an exercise price of $0.15 per share for a period of 18 months post-offering closure.
What distinguishes Kane Biotech in the market?
Kane Biotech is renowned for its substantial portfolio of intellectual property and innovative products in the biotechnology sector, particularly in combating microbial biofilms.
